Shares of Twist Bioscience (NASDAQ: TWST) , a biotech company that makes synthetic DNA-based products, including synthetic genes, antibody libraries for drug development and tools for next-generation sample preparation, jumped 25.1% in July, according to according to data from S&P Global Intelligence .
The stock closed at $34.96 on June 30, the final day of the trading month, rose to as high as $49.37 on July 21 and closed at $43.74 on July 29, the last trading day of the month. Twist's shares have a 52-week low of $25.07 and a 52-week high of $139.99 and its shares are down slightly more than 31% so far this year.
There were two prominent factors that drove up the stock's price last month. On July 14, the company announced that it was launching two monkeypox virus synthetic DNA controls, including the Congo Basin clade (genetic branch) from Central Africa and the West African clade. The controls will allow other companies developing therapies for monkeypox quality control measures for the development of next-generation sequencing (NGS) and polymerase chain reaction (PCR) assays.
For further details see:
Why Twist Bioscience's Shares Rose 25.1% in July